$11.450
+0.633 (+5.53%)Al cierre
Comparativa sectorial de TLX
In the context of the broader market, TLX competes directly with industry leaders such as CRSP and DNTH. With a market capitalization of $3.84B, it holds a significant position in the sector. When comparing efficiency, TLX's gross margin of N/A stands against CRSP's 100.00% and DNTH's 100.00%. Such benchmarking helps identify whether Telix Pharmaceuticals Limited is trading at a premium or discount relative to its financial performance.
Desempeño financiero de Telix Pharmaceuticals Ltd
Telix reported a revenue of $247 million for Q2 2026, a 21% increase year-over-year, and expects to exceed $1 billion in revenue for the full year 2026, indicating strong growth potential.
Financials
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.